Safety profile of therapeutic pox virus-based vaccines for cancer

H Kaufman(Fox Chase Cancer Center), Thomas Schuetz(Dana-Farber Cancer Institute), Dennis Panicali(Fox Chase Cancer Center), J. Marshall(Fox Chase Cancer Center), Howard Streicher(National Cancer Institute), Robert S. DiPaola(University of Kentucky), J Schlom(Fox Chase Cancer Center), Margaret von Mehren(Temple University Health System), H. Kim Lyerly(Duke University)
Journal of Clinical Oncology
July 15, 2004
10.1200/jco.2004.22.14_suppl.2513
Cited by 0

Related Papers

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Importance of the nef gene for maintenance of high virus loads and for development of AIDS
|Cell|1991|1.6k
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k